IL271606B2 - Gastro-resistant controlled release oral dosage forms - Google Patents

Gastro-resistant controlled release oral dosage forms

Info

Publication number
IL271606B2
IL271606B2 IL271606A IL27160619A IL271606B2 IL 271606 B2 IL271606 B2 IL 271606B2 IL 271606 A IL271606 A IL 271606A IL 27160619 A IL27160619 A IL 27160619A IL 271606 B2 IL271606 B2 IL 271606B2
Authority
IL
Israel
Prior art keywords
compound
dosage form
subject
gastro
resistant
Prior art date
Application number
IL271606A
Other languages
English (en)
Hebrew (he)
Other versions
IL271606B1 (en
IL271606A (en
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62904624&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL271606(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of IL271606A publication Critical patent/IL271606A/en
Publication of IL271606B1 publication Critical patent/IL271606B1/en
Publication of IL271606B2 publication Critical patent/IL271606B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL271606A 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms IL271606B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762523204P 2017-06-21 2017-06-21
PCT/US2018/038853 WO2018237207A1 (en) 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms

Publications (3)

Publication Number Publication Date
IL271606A IL271606A (en) 2020-02-27
IL271606B1 IL271606B1 (en) 2024-01-01
IL271606B2 true IL271606B2 (en) 2024-05-01

Family

ID=62904624

Family Applications (3)

Application Number Title Priority Date Filing Date
IL271606A IL271606B2 (en) 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms
IL319156A IL319156A (en) 2017-06-21 2018-06-21 Controlled-release oral dosage forms are resistant to gastric acid.
IL308650A IL308650B2 (en) 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL319156A IL319156A (en) 2017-06-21 2018-06-21 Controlled-release oral dosage forms are resistant to gastric acid.
IL308650A IL308650B2 (en) 2017-06-21 2018-06-21 Gastro-resistant controlled release oral dosage forms

Country Status (15)

Country Link
US (3) US11464744B2 (OSRAM)
EP (1) EP3641732A1 (OSRAM)
JP (3) JP2020525436A (OSRAM)
CN (1) CN111511353A (OSRAM)
AU (2) AU2018290287B2 (OSRAM)
BR (1) BR112019027398A2 (OSRAM)
CA (1) CA3067031A1 (OSRAM)
CL (1) CL2019003743A1 (OSRAM)
CO (1) CO2019014496A2 (OSRAM)
IL (3) IL271606B2 (OSRAM)
MX (1) MX2023002994A (OSRAM)
PE (1) PE20200732A1 (OSRAM)
UA (1) UA127349C2 (OSRAM)
WO (1) WO2018237207A1 (OSRAM)
ZA (1) ZA202409847B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9458130B2 (en) 2014-12-02 2016-10-04 Minerva Neurosciences, Inc. Compositions and methods for treating schizophrenia
AU2018290287B2 (en) 2017-06-21 2024-06-13 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
WO2020041504A1 (en) 2018-08-21 2020-02-27 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
IT201800011125A1 (it) * 2018-12-14 2020-06-14 Dpl Pharma S P A Composizioni farmaceutiche orali solide comprendenti matrici monolitiche complesse per la somministrazione cronotropica di medicamenti nel tratto gastroenterico
IL314859A (en) 2022-02-14 2024-10-01 Minerva Neurosciences Inc Use of roluperidone in preventing relapse in schizophrenia patients
WO2025090588A1 (en) 2023-10-24 2025-05-01 Minerva Neurosciences, Inc. Roluperidone for the treatment of lysosomal storage disorders and their symptoms

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160152597A1 (en) * 2014-12-02 2016-06-02 Minerva Neurosciences, Inc. Compositions and methods for treating schizophrenia

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3888340T2 (de) 1988-01-21 1994-06-30 Merrell Dow Pharma Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
KR927002347A (ko) 1989-10-27 1992-09-03 레이몬드 지. 아너 (n-프탈이미도알킬) 피페리딘
ATE201677T1 (de) 1992-04-23 2001-06-15 Merrell Pharma Inc 4-imidomethyl-1-(2'-phenyl-2-oxoethyl)-piperidi e als serotonin-5ht2-antagonisten, ihre herstellung und therapeutische anwendung
DE60129210T2 (de) 2000-02-29 2008-03-20 Mitsubishi Pharma Corp. Zyklische amid-derivate
MXPA03002769A (es) 2000-09-29 2003-07-28 Solvay Pharm Bv Formulacion farmaceutica de liberacion sostenida e independiente de la densidad ionica.
CA2543045C (en) 2003-10-29 2013-12-17 Wyeth Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
TW200616608A (en) 2004-07-09 2006-06-01 Forest Laboratories Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
AR057350A1 (es) 2005-06-06 2007-11-28 Merck Sharp & Dohme Derivados de ciclohexanosulfonilo como inhibidores de glyt1 para tratar esquizofrenia. composiciones farmaceuticas
AU2007212349A1 (en) 2006-02-07 2007-08-16 Mitsubishi Tanabe Pharma Corporation 4-acylaminopyridine derivative mediated neurogenesis
CA2569776A1 (en) 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
JP2008273954A (ja) 2007-03-30 2008-11-13 Mitsubishi Tanabe Pharma Corp うつ病の予防及び／又は治療剤
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
EP2246331A1 (en) 2009-04-24 2010-11-03 Westfälische Wilhelms-Universität Münster NR2B-selective NMDA-receptor antagonists
CA2762179A1 (en) * 2009-05-18 2010-11-25 Sigmoid Pharma Limited Composition comprising oil drops
MX339452B (es) 2010-06-16 2016-05-27 Teijin Pharma Ltd Tableta con nucleo recubierto de liberacion controlada.
US20130274290A1 (en) 2010-07-20 2013-10-17 Cyrenaic Pharmaceuticals, Inc. Methods of use of cyclic amide derivatives to treat sigma receptor mediated disorders
EP4494704A3 (en) 2010-07-20 2025-04-23 Minerva Neurosciences, Inc. Use of cyclic amide derivatives to treat sleep disorders
US8937900B2 (en) 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
US20120040008A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
EP2468264A1 (en) * 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
AU2012227936A1 (en) 2011-03-17 2013-10-17 Lupin Limited Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
EP2744496A4 (en) * 2011-08-16 2015-04-08 Baker Idi Heart And Diabetes Inst Holdings Ltd FORMULATIONS WITH TAXED RELEASE
CA3013541C (en) * 2013-03-14 2021-01-19 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
CN104586771B (zh) * 2013-10-30 2018-01-16 广州朗圣药业有限公司 一种盐酸坦洛新缓释微丸制剂
PE20170300A1 (es) 2014-04-30 2017-04-19 Incyte Corp Procesos para preparar un inhibidor de jak 1 y nuevas formas de este
US10208046B2 (en) 2014-05-16 2019-02-19 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
WO2016025762A1 (en) * 2014-08-13 2016-02-18 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
WO2017066134A1 (en) * 2015-10-16 2017-04-20 Merck Sharp & Dohme Corp. Processes for preparing formulations for gastrointestinal-targeted therapies
CN113694065A (zh) 2016-05-25 2021-11-26 田边三菱制药株式会社 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
AU2018290287B2 (en) 2017-06-21 2024-06-13 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
WO2020041504A1 (en) 2018-08-21 2020-02-27 Minerva Neurosciences, Inc. Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection
WO2020264486A1 (en) 2019-06-28 2020-12-30 Teva Czech Industries S.R.O Solid state forms of roluperidone and salts thereof
IL314859A (en) 2022-02-14 2024-10-01 Minerva Neurosciences Inc Use of roluperidone in preventing relapse in schizophrenia patients

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160152597A1 (en) * 2014-12-02 2016-06-02 Minerva Neurosciences, Inc. Compositions and methods for treating schizophrenia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HUSSAN SINGH DEEP ET AL.:, A REVIEW ON RECENT ADVANCES OF ENTERIC COATING, 1 November 2012 (2012-11-01) *
KAMEL SAMIR ET AL.:, PHARMACEUTICAL SIGNIFICANCE OF CELLULOSE: A REVIEW, 1 January 2008 (2008-01-01) *

Also Published As

Publication number Publication date
IL271606B1 (en) 2024-01-01
IL271606A (en) 2020-02-27
CA3067031A1 (en) 2018-12-27
IL308650B1 (en) 2025-04-01
EP3641732A1 (en) 2020-04-29
CO2019014496A2 (es) 2020-04-01
IL308650A (en) 2024-01-01
RU2020102015A (ru) 2021-07-21
CN111511353A (zh) 2020-08-07
IL308650B2 (en) 2025-08-01
US12048768B2 (en) 2024-07-30
US20250009665A1 (en) 2025-01-09
ZA202409847B (en) 2025-09-25
UA127349C2 (uk) 2023-07-26
US11464744B2 (en) 2022-10-11
AU2018290287A1 (en) 2020-01-16
JP2023175778A (ja) 2023-12-12
BR112019027398A2 (pt) 2020-07-07
CL2019003743A1 (es) 2020-07-03
IL319156A (en) 2025-04-01
AU2018290287B2 (en) 2024-06-13
MX2023002994A (es) 2023-09-15
RU2020102015A3 (OSRAM) 2021-10-04
AU2024219717A1 (en) 2024-10-03
WO2018237207A1 (en) 2018-12-27
US20220401368A1 (en) 2022-12-22
JP2020525436A (ja) 2020-08-27
US20190038561A1 (en) 2019-02-07
JP2025134828A (ja) 2025-09-17
PE20200732A1 (es) 2020-07-23

Similar Documents

Publication Publication Date Title
US12048768B2 (en) Gastro-resistant controlled release oral dosage forms
US20160256398A1 (en) Compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
US20150157575A1 (en) Pharmaceutical Formulations Comprising Vilazodone
US20240277698A1 (en) Methods of using aldosterone synthase inhibitors
EP0910375B1 (en) A composition of enalapril and losartan
Sakr et al. Pharmacokinetics of buspirone extended‐release tablets: a single‐dose study
Schussheim et al. Left ventricular midwall function improves with antihypertensive therapy and regression of left ventricular hypertrophy in patients with asymptomatic hypertension
RU2812901C2 (ru) Кишечнорастворимые лекарственные формы для перорального применения с контролируемым высвобождением
US20070053975A1 (en) Ramipril formulation
CN116234555A (zh) 改良形式的曲美他嗪的改良释放制剂
TWI841545B (zh) 耐胃性控制釋放經口劑型
KR102817359B1 (ko) 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 경구용 약학 제제
CN110755397A (zh) 一种复方降压药物片剂及其用途
Tablets et al. PrJAMP Pioglitazone
Agent PrACH-Pioglitazone
CA3268864A1 (en) ONCE DAILY ALDOSTERONE SYNTHASE INHIBITOR (R)-(+)-5-(P-CYANOPHENYL)-5,6,7,8-TETRAHYDROIMIDAZO[L,5-AjPYRIDINE
CN120018847A (zh) 每天一次的醛固酮合酶抑制剂(r)-(+)-5-(对氰基苯基)-5,6,7,8-四氢咪唑并[l,5-a]吡啶
Hydrochloride et al. PrMYLAN-PIOGLITAZONE
Agent PrJamp-Pioglitazone
NO20023463L (no) Anvendelse av rofleponid i behandling av irritabelt tarmsyndrom (IBS)
AU2017232054A1 (en) Method and composition for treating a serotonin receptor-mediated condition
KR20010031789A (ko) 퀴나프릴의 심근 허혈증 및 앙기나 치료용 용도